Johnson & Johnson to acquire Firefly Bio in $1 billion oncology push

The acquisition reflects Johnson & Johnson’s push to strengthen its position in antibody engineering and next-generation oncology modalities

NCAHP Act has built backbone of India’s healthcare workforce: Nalin Saluja, Co-Founder & CTO, Virohan

The landmark legislation has laid the foundation for a skilled, regulated and globally competitive Allied and Healthcare Professional workforce, reshaping healthcare education and delivery across India

Hoola Health raises $5 million to expand child-centric paediatric care

Bengaluru-based startup will use the fresh capital to enter new markets, enhance technology capabilities, and scale its integrated care model

FDA greenlights Lilly’s EBGLYSS for ultra-low-frequency dosing in eczema breakthrough

The move makes EBGLYSS the only therapy offering as few as six maintenance injections per year

DePuy Synthes launches AI-powered hip surgery navigation system to streamline operating room workflow

The company says the goal is to improve consistency and efficiency in total hip arthroplasty (THA) as demand for the procedure continues to surge

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide

The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format

Eli Lilly's oral weight-loss drug shows major fat loss across stages of menopause in trials

The results come from post-hoc analyses of more than 1,500 women enrolled in the Phase 3 ATTAIN-1 and ATTAIN-2 trials, presented at the American Diabetes Association’s 86th Scientific Sessions

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Agilus’s Idylla claims to deliver cancer mutation results in just 3 hours

Advanced molecular diagnostics solution enables rapid, high-accuracy biomarker detection for precision oncology